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Summar- ErbB-2 and EGFR (epidermal growth factor receptor) are expressed in lung adenocarcinomas and
associated with a poor prognosis. Immunocytochemical analysis revealed erbB-2 and EGFR coexpression as a
characteristic feature of most lung adenocarcinomas, and at levels of receptor expression present in bronchial
epithelial cells. In primary lung tumours and cell lines. erbB-2 detected using Western blot analysis demon-
strated low-level phosphotyrosine staining of the 185 kDa band, as compared with breast cancer cell lines.
A549 and A427 lung adenocarcinoma cells treated with neu differentiation factor (NDF) showed increased
erbB-2 phosphotyrosine staining, but to a much lesser extent than breast cancer cells. The lung cells were
examined for expression of the potential autocrine growth factors NDF and transforming growth factor m
(TGF-a) by Northern blot analysis. Both NDF and TFG-a mRNA were abundantly expressed in the A549
cells. NDF mRNA was highest during active cell proliferation and decreased in confluent cells or after
treatment with the growth-inhibitory steroid dexamethasone. Primary tumours and cell lines expressed EGFR.
shoWing higher basal level phosphotyrosine staining than erbB-2. Treatment with NDF and EGF (epidermal
growth factor) stimulated cell growth. and in A549 cells the presence of both factors provided an additive
increase in cell growth. The growth stimulus that ligand-activated erbB-2 and EGFR provides to lung
adenocarcinoma cells may establish a background of continued cell proliferation over which other critical
transforming events may occur.
Keywords.- lung cancer: receptor: cells; EGFR: erbB-2
ErbB-2 and EGFR are homologous membrane-bound recep-
tors with tvrosine kinase activity which are expressed in
many fetal and adult epithelia and are thought to play a role
in the growth and differentiation of these normal tissues
(Press et al.. 1990: Suda et alt. 1990; Madtes, 1993). Over-
expression of erbB-2 and EGFR has been identified in a
variety of epithelial tumours and has been extensively studied
in breast and lung cancer. In lung adenocarcinomas, erbB-2
overexpression relative to normal alveolar lung tissue has
been found to correlate with a worse prognosis (Kern et al..
1990). EGFR overexpression in conjunction with autocrine
ligand expression may also be associated with a worse prog-
nosis in lung adenocarcinoma (Tateishi et al.. 1990: Diattadi
et al.. 1991: Pavelic et al., 1993: Veale et al.. 1993). The
association between overexpression of erbB-2 and EGFR
with poor prognosis suggests that their overexpression may
contribute to lung adenocarcinoma tumorigenesis and metas-
tatic potential.
Despite the association with expression and poor prog-
nosis, the exact role that erbB-2 or EGFR overexpression
plays in lung adenocarcinoma development remains unclear.
Malignant transformation by transfection of the EGFR
alone has not yet been demonstrated, but it can induce
mitogenesis in vitro after binding either EGF or transforming
growth factor a (TGFa) (Velu et al., 1987; Di Marco et al..
1989). The transfection and overexpression of erbB-2 can
confer tumorigenicity on immortalised fibroblasts (Chazin et
al., 1992) but is insufficient to induce malignant transforma-
tion in transfected immortalised human bronchial epithelial
cells (Noguchi et al.. 1993) or in transgenic mice (Stocklin et
al.. 1993). However. transfection and overexpression of erbB-
2 have been show%n to enhance lung cancer cell metastatic
potential (Yu et al.. 1994). It appears that erbB-2 and EGFR
overexpression contributes to. but may be insufficient for,
tumorigenesis in lung adenocarcinoma.
Signal regulation and tumorigenesis of erbB-2 and EGFR
are dependent on their tyrosine kinase activity (Segatto et al.,
1990). ErbB-2 and EGFR are thought to interact by trans-
phosphorylation via heterodimer formation, resulting in en-
hanced ligand affinity (Kokai et al., 1988; Connelly and
Stern, 1990; Wada et al., 1990). Expression of both receptors
in a tumour cell may allow interaction between the two
receptor types, modifying signal transduction in a way that
could contribute to tumorigenesis. We hypothesise that erbB-
2 and EGFR coexpression may provide a cooperative growth
stimulus and therefore would be a selected characteristic of
lung adenocarcinomas. This study was undertaken to estab-
lish the frequency of erbB-2 and EGFR coexpression in lung
adenocarcinomas. In addition. established lung adenocar-
cinoma cell lines were used to examine the potential role of
erbB-2 and EGFR in lung tumorigenesis by determining the
expression of these receptors. their steady-state activation
status and the effect of erbB-2 and EGFR ligand-mediated
activation on cell growth.
Materials and methods
Human tissues
Samples of normal lung and lung tumour were obtained after
informed consent from patients undergoing operation for
lung cancer at the University of Michigan between August 91
and April 94. Additionally, samples of bronchial epithelium
free of tumour were obtained from a subset of the same
patients. Analyses were performed on tissues from patients
with the final diagnosis of primary lung adenocarcinoma.
Immediately upon resection. specimens were divided into
thirds. The middle third was embedded in OCT compound
(Miles. Elkhart, IN, USA), frozen in isopentane cooled to the
temperature of liquid nitrogen and used for cryostat section-
ing and subsequent immunocytochemistry. The other two
portions were frozen in liquid nitrogen and used for RNA
and protein isolation. Samples were stored at - 70'C until
analysed.
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The final hospital pathology reports of all patients were
reviewed and used to establish the histology and the stage of
the tumours. Tumours were staged according to the AJCCS
system (American Joint Committee on Cancer Staging. 1992).
Cell lines
Human lung adenocarcinoma cell lines A549, A427 and
SKLU-1 were obtained from American Type Culture Collec-
tion (ATCC) (Rockville, MD. USA) and breast cell lines
SKBR3 and MCF-1OA (MCFIO) were obtained from the
Michigan Cancer Foundation (Detroit MI, USA). The SUM-
52PE cell line (SUM52) was derived from a malignant pleural
effusion of a breast carcinoma patient in our laboratory. Cell
lines were grown in media specified by the ATCC. except
SUM-52 cells, which were grown in serum-free media (SFM)
consisting of Ham's F12 (Sigma, St Louis, MO, USA),
1 mg ml' bovine serum albumin (BSA), 1 mg ml- insulin,
5 mM ethanolamine, 10 mM Hepes, 5 jig ml-' transferrin,
10 i1M T3 and 50 gM selenum with or without 5% fetal
bovine serum (FBS) (Ethier, 1993). All media were supp-
lemented with 0.05 ,g m1-' fungizone (JRH Bio Sciences,
Lenexa, KS, USA) and 5;Lgml-' gentamicin (Gibco BRL
Life Sciences, Grand Island, NY, USA). Cells were washed
with phosphate-buffered saline (PBS), pelleted and then
stored at - 70°C for subsequent RNA and protein isolation.
Cells used for immunocytochemical analysis were cytospun
onto poly-L-lysine-coated slides.
The effect of cell confluence on NDF, erbB-2 and EGFR
mRNA expression was determined by splitting a near-
confluent plate of A549 or A427 cells approximately 1:20
into 100mm culture plates, incubating cells in appropriate
medium supplemented with 10% FBS, and then harvesting
cells on days 1, 2, 4 and 7 for RNA isolation. Cells were
noted to be confluent on day 4. The effect of dexamethasone
treatment on NDF and erbB-2 mRNA was determined by
splitting near-confluent plates of A549 or A427 cells into
100mm plates with 1 x 106 cells per plate, and incubating
cells in appropriate medium supplemented with 10% FBS
overnight. Medium was removed, cells washed with PBS, and
medium was replaced in duplicate plates with steroid-stripped
10% FBS medium (Hanson et al., 1991) with either 0, 100 or
1000 nM dexamethasone (Sigma). Duplicate plates were
prepared for each experimental group. Cells were allowed to
grow until plates were approximately 90% confluent, and
then harvested for Northern blot analysis as described below.
.Northern blot anal vsis
Total RNA was isolated from tissues and cell lines using
Tri-Reagent (Molecular Research Center, Cincinnati, OH,
USA) following the manufacturer's protocol. Ten micro-
grams of total cellular RNA per sample was separated by
electrophoresis in 1.2% agarose gels containing 2.2 M for-
maldehyde and then vacuum transferred to nylon membranes
(Gene Screen Plus: NEN, Wilmington, DE, USA). Mem-
branes were prehybridised in 5 x SSPE (0.9 M sodium chlor-
ide. 50 mM sodium phosphate. pH 7.7, and 5 mM EDTA),
5 x Denhardt's, 50% formamide. 3% SDS, 5% dextran
sulphate. 5 mg ml-' heat-denatured salmon sperm DNA and
3 ;tg ml- 1 yeast tRNA for 1 h at 48'C. Probes were labelled
with [3'P]dCTP by the random primer labelling method
(Prime-It II, Stratagene. La Jolla. CA. USA) and purified by
Sephadex G-50 exclusion chromatography. Membranes were
hybridised with 1.5 x 1o6 c.p.m. ml-' heat-denatured, labelled
probe for 16-18 h in a 48'C shaking water bath. Membranes
were washed according to the manufacturer's recommenda-
tions and autoradiograms prepared (Hyperfilm-MP; Amer-
sham. Arlington Heights. IL. USA). Loading and transfer of
RNA were normalised using a probe for 28S rRNA as
previously described (Hanson et al.. 1991).
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cDNA probes
DNA probes used included: a 2.5 Kb Clal fragment of the
human EGFR cDNA (Xu et al.. 1984). a 1.6 Kb EcoRI
fragment of the human erbB-2 cDNA (Di Fiore et al.. 1987).
human TGFaE cDNA insert (Derynck et al.. 1984). and
human NDFx2 insert (Holmes et al.. 1992).
Immunocvtochemistrv
Immunocytochemistry was performed on 5 gm cryostat sec-
tions of normal lung, lung adenocarcinoma and bronchial
epithelium as well as using cytospun cell lines. Monoclonal
antibody to erbB-2 (Ab-2. clone 9G6) was obtained from
Oncogene Science Inc.. (Uniondale. NY. USA) and used at a
dilution of 1:100. Monoclonal antibodv to EGFR was
obtained from Triton Diagnostics (Alameda. CA. USA) and
used at a dilution of 1:5. Control reactions consisted of
incubations without the primary antibodies. A standard
avidin-biotin-peroxidase complex method With 3.3'-
diaminobenzidine as the chromagen was used according to
the manufacturer's recommendations (Vecta-Stain-Elite. Vec-
tor Laboratories Inc., Burlingame. CA. USA). All sections
were examined by two observers and classified as either
present or absent, and when present. as either
homogeneously expressed in all cancer cells or variably exp-
ressed.
W'estern blot anal!ysis
Membrane protein was isolated from tissues and cell lines bv
homogenising near-confluent cell plates or approximately 1 g
tissue samples in membrane lysis buffer (20 mm Hepes. 5 mm
sodium orthovanadate. 10 mM sodium pyrophosphate and
1 mM phenylmethylsulphonyl fluoride). These supernatants
were ultracentrifuged at 100 000g for 30 min. and the pellet
resuspended in Western lysis buffer (10 mM sodium phos-
phate, 100mM sodium chloride. 1% Triton X-100. 0.50'o
sodium deoxycholate, 0.1% SDS, 5mM sodium orthovana-
date. 10 mM sodium pyrophosphate and 1 mM phenylmethyl-
sulphonyl fluoride). Protein concentrations were quantified
using the colorimetric micro-Lowry method (Sigma). Either
75 or 100pg of sample protein was loaded per lane. or the
total sample protein isolated was divided equally between
compared samples. In all cases, compared samples contained
equal amounts of protein. Samples were boiled for 5 min.
loaded and separated by electrophoresis on a 7.5% SDS-
PAGE gel along with high-range molecular weight markers
(Bio-Rad Laboratories. Richmond, CA. USA). The gel was
then electrotransferred to a PVDF membrane for immuno-
blotting. Membranes were blocked in 0.1% Tween 20.
100 mM Tris base, 0.9% sodium chloride and 3% powdered
milk solution for 1 h. Avidin-biotin complex staining was
performed using polyclonal erbB-2 (9.3 anti-erbB-2. a
generous gift from Dr Beatrice Langton. Berlex Biosciences.
Richmond. CA. USA). monoclonal EGFR (Triton Diagnos-
tics. Alameda. CA, USA) or monoclonal phosphotyrosine
antibody (PY20, ICN Biomedicals, Costa Mesa. CA. USA).
Immunoprecipitation Western blots were performed in a
similar fashion except that cells or tissue membrane protein
was incubated in primary antibody (polyclonal erbB-2) for
2 h. and then incubated in 50 ytL of protein A -agarose
(Sigma) for 1 h. Protein A beads were then spun out, the
precipitate resuspended. and gels and blots were prepared as
described above.
Growth assays
Cell lines were plated at low density using three 60-mm plates
for each experimental group and then incubated in F12
Ham's with 10% FBS overnight. Three plates were then
counted to determine initial plating density (time zero). The
F12 Ham's with 10% FBS was then removed and triplicate
plates were treated with one of the following: F12 10% FBS.
SFM (serum-free medium). SFM plus 10ng ml-' NDF P3 (a
generous gift from Amgen. Thousand Oaks. CA. USA).EGR an erbB-2 in- tumoms
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Fgre I Immunocytochemical localisation of erbB-2 and EGFR protein expression in primary human lung adenocarcinomas and
established cell lines. (a) ErbB-2 membranous staining is observed on all primary lung adenocarcinoma cells but not on supporting
stromal cells. (b) Serial section of primary lung adenocarcinoma shown in a, demonstrating co-localisation of EGFR membranous
staining on tumour cells also expressing erbB-2. (c) Control section of area shown in a and b stained without primary antibody. (d)
Bronchial epithelium from patient with primary lung adenocarcinoma demonstrating erbB-2 expression in all cell layers of the
epithelium. (e) Serial section of bronchiolar epithelium shown in d stained for EGFR. Only the basal cel layer of the bronchial
epithelium appears to express EGFR (arrows). (f) Control section of area shown in d and e stained without primary antibody. (g)
The SKBR3 breast cancer cell line abundantly expresses erbB-2 protein but, as shown in h, relatively less of the EGFR. (i)
Expression oferbB-2 in the A549 lung adenocarcinoma cell line. (j) EGFR expression in A549 cels. (k) Expression of erbB-2 in the
A427 lung adenocarcinoma cell line. (1) EGFR expression in A427 cells. Al cryostat sections and cytospun cells were lightly
counterstained with haematoxylin. Scale bars = 20jm.-Ff Ji h2 gbi_s
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SFM plus 10 ng ml epidermal growth factor (EGF) and SFM
plus NDF and EGF. Cells were grown for 1 week, nuclei
isolated using Bretol solution containing ethyihexadecyldi-
methyl ammonium bromide (Eastman Kodak, Rochester,
NY, USA) and glacial acetic acid, and then counted a
Coulter Counter as by the manufacturer
(Coulter Electronics, Hialeah, Fl, USA). Counts were coin-
cidence corrected and analysed by analysis of variance with
Fisher's protected least signifiant difference post-hoc testing
(StatView statistl program, Abacus Conceptions, Berkeley,
CA, USA).
Rest
Expreswion oferbB-2 andEGFR
Immunocytochemical analysis was used to determine the fre-
quency of erbB-2 and EGFR protein coxpresson in 43
prinmry human lung adenocarcinomas as well as the thre
cell lines (A549, A427 and SKLU-1) derived from human
hmg adenoarcinomas. The staining patterns of normal
alveolar tissues and bronchial t samples were also
determined from patients with hmg adenocarcinoma. All his-
tologically normal alveolar tissues examined were negati
for erbB-2 and EGFR protein e on. All 43 tumours
examined demonstrated a membranous erbB-2 protein stain-
ing pattern (Figure la). EGFR protein was de d in 36
out of the 43 tumours (Figure lb). ErbB-2 and EGFR coex-
pression was therefore det in 83% of lung adeocar-
cinomas. Seven of the 36 coexprssing tumours demonstrated
non-uniform staning for EGFR, in which saining was not
observed on all tumour cells. Several coexpressing tumour
sections contained adjacent normal alveolar tissue, highlight-
ing the relative overexpression of erbB-2 or EGFR in the
tumour as compared with the absent expresion in the
alveolar tissue (not shown). These results are consistent with
previous reports ofthe low klvel or absent epson of these
a
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receptors in normal lung alveolar tissue (Rusch et al., 1993;
Bongiorno et al., 1994). In contrast, five out of five his-
tologically normal bronchial epitheium samples coexpressed
erbB-2 and EGFR at levels similar to that seen in the
primary tumours (Figure Id and e). The staining of EGFR in
the normal bronchial epithelium was limited to the basal cell
layer, while erbB-2 was present throughout the pseudost-
ratified architecture (Figure Id).
ErbB-2 and EGFR expression status relative to tumour
stage at time ofresection is shown in Table I. Tumours with
variable or absent expresson of EGFR tended to be of a
higher stage than tumours showing uniform erbB-2 and
EGFR expression. The distibution of tumour stages in these
surgical patients, however, is not representative of that seen
in all lung cancer patients, since most patients with either
known stage m or IV disease are excluded from pulmonary
resection.
Human lung adenocarcinoma cell lines A549, A427 and
SKLU-1 were evaluated for erbB-2 and EGFR expresson
usng immunocytochemical techniques, as was done in the
primary tumours Each cell line demonstrated erbB-2 staining
similar to the prinary lung mas, but less than
SKBR3, a breast a arcmoma cell ie containing amp-
lified and overexpressed erbB-2 which served as a positive
control (Figure Ig). EGFR was also xprssa in the lung
lines and SKBR3 cells. These results are consistet with
TAI I ErbB-2 and EGFR expression in 43 primary hlng
compared with patient's surgical stage
ErbB-2 and ErbB-2 with ErbB-2 with
AJCC stage EGFR var*ibl EGFR absent EGFR
I 17 2 3
II 4 0 0
III 7 5 4
IV 1 0 0
Total 29 7r r
aSignificantly higher stage by Fses exact test (P<0.05).
b
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Flgwe 2 Northern blot analysis of erbB-2, EGFR and NDF xreson a pmary lung and
lnes. (a) ErbB-2 and EGFR mRNA in a primary hmg (AC), the three hmg
A549, SKLUI and A427, the olon ca ercdl line HT29 and the breast cancr cedl line SKBR3. (b) Ex oferbB-2, EGFR
and NDF mRNA in A549 and A427 ccels duing actiw cell groth (days and 2) and conflun (days 4 and 7). A549 clils were
beyond confluenc on day 7. 28S RNA was usd as a contrl for lkding and transfer for both a and b.
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Northern blot analysis, which demonstrated relatively similar
levels oferbB-2 and EGFR mRNA levels in the cell lines and
in a lung adenocarcinoma, with the exception of A549 cells,
which expressed higher levels of EGFR mRNA (Figure 2a).
SKBR3 demonstrated substantially higher levels of erbB-2
mRNA than the lung tumours or cell lnes.
A similar level of erbB-2 expression was obwrved in all
cells ofthe primary tumour specmens eamined by immuno-
cytochemcal analysis. Further, A549 cells analysed by
Northern blot also demonstrated similar levels of erbB-2
mRNA in both growing and confluent cells (Figure 2b),
suggesting that erbB-2 expresson is independent of rate of
cell growth within the tumour. A549 cells treated with dex-
amethasone, which is known to inhibit A549 cell growth and
induce some differentiated features (Speirs et at., 1991; Crox-
tall et al., 1993), also did not alter the levels of erbB-2
mRNA (data not shown). In contrast, EGFR protein expres-
sion was found to be variable in some primary tumours,
suggesting that its expression may be affected by the growth
state of individual cells. Similarly, A549 cells grown to
different degrees of confluence demonstrated increased
EGFR mRNA levels during subconfluent cell growth and
decreased levels with cell confluence (Figure 2b). These
results are consistent with EGFR protein expresson in bron-
chiolar epithelium, w the highest expression is present in
the prolferatng basal cells (Figure le).
Autocrie ligandexpression
Tumour cells may maintain constant levels of the erbB-2
receptor protein, but the expression of autocrine lgands for
erbB-2 and EGFR may be major determinants for receptor
activation and cell growth. Thefore, lung adenocarcinoma
cell lines A549, A427 and SKLU1 were evaluated by North-
ern blot analysis for the expression of NDF and TGF-4
mRNA, the ligands capable of activating erbB-2 and EGFR
respUecively. A549 cells expressed abundant mRNA for both
NDF and TGF.<a, while A427 expressed only small amounts
of TGF-a mRNA (Figure 3a). HT-29 colon cancer cells
a
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expressed abundant TGF-x mRNA and SKBR3 breast
cancer cells expressed potentially truncated forms of TGF-x
mRNA. Interestingly, expression of NDF mRNA was
highest in rapidly dividing, subconfluent A549 cells, and
decreased as cells became confluent (Figure 2b). Similarly,
treatment of A549 cell lines with growth-inhibitory concen-
trations ofdexamethasone (Speirs et al., 1991; Croxtall et al.,
1993) also inhibited NDF mRNA in a dose-dependent man-
ner (Figure 3b). The association between high NDF mRNA
expresson and rapid cell growth would be consistent with
NDF acting as an autocrine growth factor in these cells.
Activation oferbB-2 andEGFR
If erbB-2 and EGFR are contributing to tumorigenesis in
lung adenocaranomas it would be expected that these rep-
tors would show evidence ofactivation. Activation of erbB-2
and EGFR in cell lnes and tumours was therefore assessed
by xamining receptor tyrosne phosphorylation using a PY-
20 antiphosphotyrosine antibody and Western blot analysis.
Tyrosne kinase activity is known to be assocated with
autophosphorylation of these receptors (Segatto et al., 1990).
The SKBR3 breast cells served as a positive control. The
A549 lung crcinoma cells and five primary lung adenocar-
cinoma specim were examined. Western blot analysis dem-
onstrated a 185 kDa erbB-2 protein in the A549 ells and
prinary tumours, however little corresponding phospho-
tyro staining of 185 kDa proteins was present (Figure
4a). The SKBR3 cells contained a strong 185 kDa staining
band with both erbB-2 and PY-20 antibodsie, demonstrating
high-level constitutive activation of erbB-2 in these cells. A
175 IDa protein corresponding to the size of the EGFR was
detectd using an anti-EGFR antibody in three out of four
tumours. Unlike the erbB-2 protein, the EGFR was assoc-
iated with a corresponding phosphotyrosine staining band, or
possibly a doublet band, at 175 kDa. To detrmine whether
freezing and thawing of the primary tumours before prepar-
ing protein extracs affected phosphotyrosine staining, A549
cell pellets were frozen at - 70-C, and phosphotyrosine stain-
b
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Fugwe 3 Northern blot analysis of NDF and TGF-a mRNA is establshed oell lines. (a) NDF and TGF-a mRNA expression in
the lung cell lines A549, A427, SKLU1, in the colon canr cel line HT29 and in the breast cancer cell line
SKBR3. (b) NDF mRNA expei in A549 cells following trtment for 24h with the final concentrations of d
indicated Dupicate samples are shown. 28S rRNA expresson was used as a control for lading and transfer for both a and b.
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Figure 4 Western blot analysis of erbB-2, EGFR and PY-20 phosphotyrosine antibody staining in primary lung tumours and
established cell lines. (a) The expression of the 185 kDa erbB-2 protein and the 175 kDa EGFR protein in primary lung
adenocarcinoma tumours (ACI-AC5) and the lung cell lines A549 and the breast cell line SKBR3 is indicated by arrows.
Activation oferbB-2 or EGFR is inferred by the presence of PY-20 phosphotyrosine antibody staining at the bands corresponding
to the 185 kDa erbB-2 or 175 kDa EGFR proteins. The molecular weight markers (marker) are shown for protein size reference.
Total protein isolated from the A549, SKBR3 and AC-1 samples were divided equally between blots used for erbB-2 and PY-20
phosphotyrosine staining. AC2-AC5 each had 100mg of protein loaded per sample. (b) Western blot analysis of erbB-2, EGFR
and PY-20 phosphotyrosine antibody staining of the lung adenocarcinoma cell lines A549, A427 and the breast cancer cell line
SUM52. The A549-sf cells were grown under serum-free conditions. The molcular weight marker (marker) is shown for protein
size reference. Each sample lane contained 100 Lg of isolated protein.
ing was compared with that of freshly harvested A549 cells.
No change in phosphotyrosine staining pattern or intensity
was observed. Thus, in primary lung adenocarcinomas, phos-
photyrosine staining was more pronounced in the EGFR
protein than in the erbB-2 protein.
To examine further the factors affecting erbB-2 and EGFR
activation in the three lung adenocarcinoma cell lines, the
A549, A427 and SKLU-1 (not shown) were analysed using
Western blots and compared with the breast cell lines MCF-
10 and SUM52. All three lung adenocarcinoma cell lines
expressed the erbB-2 protein at 185 kDa, but little basal level
phosphotyrosine staining at 185 kDa was observed (Figure
4b). Instead, A549 cells expressed more EGFR protein and
relatively higher levels of the corresponding phosphotyrosine
staining protein at 175 kDa than A427 cells. A549 cells
showed little difference in phosphotyrosine staining of the
EGFR band in either the presence or absence of FBS. The
increased 175 kDa phosphotyrosine staining of the EGFR
band in the A549 vs the A427 cells is consistent with the
higher level of EGFR protein (Figure lj and 1) and EGFR
mRNA (Figure 2a) in these cells. The SUM52 cells do not
express the 175 kDa EGFR band, but contain a strong
185 kDa band that is associated with phosphotyrosine stain-
ing. SUM52 and SKBR3 breast cancer cells demonstrated
higher basal-level erbB-2 phosphotyrosine staining than
either the lung adenocarcinoma cell lines or the primary lung
tumours. Western blots of immunoprecipitated erbB-2 from
the A549 cells was also unable to detect phosphotyrosine
staining, while SKBR3 cells were positive (data not shown).
This may be due to the lower level of total erbB-2 protein
present in the lung cells. ErbB-2 and EGFR activation in the
lung adenocarcinoma cell lines was therefore similar to that
present in the primary tumours.
To determine if erbB-2 or EGFR phosphotyrosine staining
could be enhanced above basal levels, lung cell lines were
treated with NDF and/or EGF. NDF treatment of A549 and
A427 resulted in a slight increase in the phosphotyrosine
staining of the 185 kDa band corresponding to the erbB-2
protein (Figure 5a). This increase was much less than that
seen in the breast cell line MCF1O, which had marked
enhancement of the 185 kDa phosphotyrosine band following
NDF treatment (Figure 5a). Treatment ofA549 cells with the
antibody Tab-250, which has erbB-2 ligand-like properties in
some cells, did not increase PY-20 staining of erbB-2. Addi-
tion of EGF to A549 cells did increase PY-20 phospho-
tyrosine staining associated with EGFR, as compared with
either NDF treatment or under serum-free conditions (Figure
5b). Treatment with both NDF and EGF did not increase
the extent of PY-20 staining of either the 175 kDa EGFR or
the 185 kDa erbB-2 bands over that observed with either
factor alone.
Growth ofcells with NDFand EGF treatment
A549 cells grown in SFM demonstrated a 14-fold increase in
cell number after 1-week (Figure 6). This suggests that these
cells produce autocrine growth factors, and thus is consistent
with the presence of TGF-a and NDF mRNA expressed in
these cells (Figure 3a). A427 cells grown in SFM demon-
strated a 5-fold increase in cell number after 1 week (data not
shown). The increased autocrine ligand expression in A549
cells corresponded with greater growth under serum-free con-
ditions observed with these cells as compared with A427 cells
(Figure 3a). SKLU1 cells did not express significant levels of
either ligand, and demonstrated little capacity to grow under
serum-free conditions (data not shown). A549 cells treated
with SFM plus NDF or EGF had a statistically significant
increase in cell growth over SFM alone. NDF plus EGF
treatment in A549 cells had an additive effect on cell growth,
equal to that obtained with 10% FBS-supplemented medium.EGFR an wbB-2 i hun btmows
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F re 5 Potential activation of erbB-2 and EGFR in A549 and
A427 lung adenocarcinoma cells and in MCFI0 breast cells by
NDF and EGF ligands. (a) ErbB-2 and PY-20 phosphotyrosine
antibody staining of A549 and A427 lung adenocarcinoma cell
lines and the MCF10 breast cell line grown under serum-free
conditions and compared with serum-free conditions plus 1Ong
ml-' NDF treatment for 1 h. ErbB-2 expression in A549 and
A427 cells is shown for reference. A427-Tab were A427 cells
incubated with the TAB 250 erbB-2 antibody for I h. A549 and
MCF1O cell samples contained 75 iLg of isolated protein, while
A427 samples contained 100iLg of isolated protein. (b) A549 cells
grown under serum-free conditions and treated with either
lOngmrV1 NDF, EGF or both ligands for I h. Protein size
marker and erbB-2 staining of A549-SF are included for
reference. All samples contained 100 lg of isolated protein.
Growth of A427 cells in SFM plus NDF was also signi-
ficantly greater than in SFM alone (data not shown). EGF
treatment of A427 cells, however, added little to the growth
stimulation provided by NDF alone, and was variably
stimulatory or inhibitory. The reasons for this are unclear
but may relate to the expression of the EGFR in cells grown
at different plating densities.
Dosi
Overexpression without gene amplification of erbB-2 and
EGFR has been described in a subset of lung adenocar-
cinomas (Slamon et al., 1989; Kern et al., 1990; Rusch et al.,
1993). In vitro studies suggest that erbB-2 and EGFR may
interact through heterodimer formation or transphosphoryla-
tion (Kokai et al., 1988; Wada et al., 1990). In breast cancer,
erbB-2 and EGFR coexpression correlates with a poor prog-
nosis (Osaki et al., 1992), and amplification of these genes is
more commonly observed. Information that these receptors
may interact to contnibute to tumorigenesis led us to evaluate
their coexpression in primary lung adenocarcinomas. Inter-
estingly, all 43 (100%) lung adenocarcinoma tumours exam-
ined expressed erbB-2 protein, and 36 (83%) of these also
expressed EGFR protein. All three lung adenocarcinoma cell
lines examined also expressed both receptors. ErbB-2 and
EGFR coexpression is therefore characteristic of most lung
adenocarcinomas. The frequency of erbB-2 and EGFR coex-
pression reported in this study is higher than previously
reported (Scagliotti et al., 1993), possibly reflecting the
enhanced sensitivity from using frozen rather than paraffin
sections (Press et al., 1994). Our studies suggest that con-
tinued expression of these receptors, and not necessarily
overexpression, may be the most significant feature in lung
adenocarcinomas.
To determine if the pattern and degree of erbB-2 and
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Figure 6 The effect of serum. EGF and NDF on A549 cell
growth. A549 cells were grown for 1 week in either medium
containing 10% FBS (Serum), serum-free medium (SFM), 10 ng
ml- NDF, 10 ng ml-' EGF or 10 ng ml-' NDF plus 10 ngml-'
EGF. The number of cells plated at time zero for each condition
is indicated (Start). Mean cell number of triplicate plates is
shown. Error bar represents the confidence interval of the mean
cell number. *Statistically significant (P<0.05) difference in the
mean cell number as compared with SFM using analysis of
variance. *Statistically significant (P<0.05) difference in the
mean cell number as compared with either SFM, NDF or EGF
treatments.
EGFR expression found in lung adenocarcinomas was
different from that found in normal tissues, we examined
their expression in normal bronchiolar and alveolar epithelial
tissues. All alveolar lung tissue examined was negative for
erbB-2, as we have previously reported (Bongiorno et al.,
1994). EGFR expression was very low, with only scattered
cellular staining in this tissue. consistent with previous
reports (Rusch et al., 1993). Bronchial epithelium, however,
was found to express both erbB-2 and EGFR, consistent
with previous reports (Dazzi et al., 1989; Weiner et al., 1990),
and suggests that the bronchial epithelium may be the cells of
origin for lung adenocarcinomas. ErbB-2 and EGFR expres-
sion in the lung adenocarcinomas may therefore represent a
normal level of expression present in bronchial epithelial cells
rather than overexpression from transformed alveolar tissue
levels. One must consider, however, that the bronchial
epithelium from cancer patients examined in this study may
in fact be abnormally expressing erbB-2 or EGFR. Evidence
suggests that some bronchial epithelium from cancer patients
may have cytogenetic abnormalities (Sozzi et al., 1991). In
addition, other normal tissues, such as pharyngeal epithe-
lium, have been shown to have increased expression of
EGFR directly adjacent to tumour tissue (Shin et al., 1994).
A field effect of premalignant change in the bronchial
epithelium therefore may affect erbB-2 and EGFR expres-
sion, which in turn could stimulate growth and predispose
these cells to additional genetic events.
EGFR protein staining was observed only in the pro-
liferative basal cell layer of the bronchial epithelium, while
erbB-2 immunoreactivity was expressed throughout the pseu-
dostratified architecture. Staining of EGFR in the basal
layer, which is decreased in more luminal layers, suggests
that this receptor may play a role in normal growth and
differentiation of the bronchiolar cells. Expression of EGFR
in primary tumours may vary depending on the growth state
of individual cells. ErbB-2 expression may be independent of
the growth or differentiated state of either bronchial epi-
thelial cells or tumour cells since it is expressed throughout
the bronchial epithelium and uniformly in tumours. A similar
phenomenon was observed in vitro with A549 cells, in which
the levels of erbB-2 mRNA were similar during active cell
growth or confluence. In contrast, EGFR mRNA levels were
highest in rapidly growing cells (Figure 3), and this is consis-
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tent with the higher EGFR protein levels in the proliferating
basal cells of the bronchiolar epithelium.
Signal regulation by erbB-2 and EGFR is dependent on
their tyrosine kinase activity. When lung adenocarcinoma
tissues or cell lines were examined for activation by Western
blot analysis, low-level EGFR and very little erbB-2 activa-
tion was detected. This suggests that the transforming poten-
tial of erbB-2 in lung adenocarcinomas does not involve
constitutive activation of intrinsic tyrosine kinases in the
absence of ligand as may occur in breast cells with amplified
erbB-2 genes. Even in A549 cells, which produce both NDF
and TGF-a mRNA (Figure 3a), ligands potentially capable
of activating erbB-2 and EGFR respectively, only low-level
erbB-2 activation is detected. Treatment of A549 and A427
cells with NDF increased the phosphotyrosine staining of the
185 kDa erbB-2 band in these cells, indicating that the recep-
tors can be activated, however the level of activation was
always less than that observed in the breast cell lines. Thus
erbB-2 activation in lung adenocarcinoma tumours and cell
lines is distinctly different from that of breast tissue. MCF1O
benign mammary epithelial cells have low basal-level activa-
tion of erbB-2 similar to lung adenocarcinomas, but demon-
strate a much greater capacity for activation by NDF. The
SUM52 breast cancer cell line, which overexpresses erbB-2
protein without gene amplification, demonstrates greater
basal-level activation oferbB-2 than is seen in lung adenocar-
cinoma cells. Amplification of erbB-2 in SKBR3 is associated
with constitutive activation of greatly overexpressed erbB-2
protein. Amplification of erbB-2 expression is present in up
to 30% of breast cancers and is associated with a worse
patient prognosis independent of stage (Slamon et al., 1987),
possibly related to constitutive activation of erbB-2 tyrosine
kinase. These differences between the lung and breast systems
may relate to the absolute amounts of erbB-2 expressed, or
may be related to the absence or presence of co-factors
necessary for the activation of erbB-2 by NDF, such as
erbB-3 or erbB4 (Akita et al.. 1994; Plowman et al., 1994) or
cell specific factors (Peles et al., 1993). We are currently
examining whether the lung adenocarcinoma cells express
either erbB-3 or erbB-4. It appears, therefore, that the role of
erbB-2 in lung tumorigenesis differs from that of breast in
both the frequency of amplification with constitutive activa-
tion and the capacity to be activated by NDF.
Growth assays of A549 and A427 demonstrate the cap-
acity of these cells to grow under serum-free conditions.
Autocrine growth factors NDF and TGF-a, produced by
both lines, probably play a contributory role in their serum-
free growth. Treatment of A549 and A427 with NDF further
enhanced activation and stimulated cell growth above that of
serum-free medium, demonstrating functional yet low-level
activation in these cells. The relatively greater activation of
EGFR relative to erbB-2 in both the lung cell lines and
primary tumours, as demonstrated by Western blot staining
for phosphotyrosine, may suggest that expression of erbB-2
may facilitate EGFR activation. ErbB-2 and EGFR are
thought to interact by transphosphorylation via heterodimer
formation, resulting in enhanced ligand affinity for the
EGFR (Kokai et al., 1988; Connelly et al., 1990; Wada et al.,
1990). A549, interestingly, demonstrated an additive growth
stimulus with NDF and EGF, suggesting a cooperative role
between erbB-2 and EGFR, one that may exist in tumours
coexpressing these receptors. Other transforming characteris-
tics such as p53 and K-ras mutations are present in these cell
lines (Lehman et al., 1991), potentially contributing to their
serum-free growth. Similarly, primary lung adenocarcinomas
also contain alterations such as p53 and K-ras mutations
(Bongiorno et al., 1994), which may affect cell growth,
invasive and metastatic properties. ErbB-2 and EGFR exp-
ression may therefore provide a cooperative ligand-dependent
growth stimulus to bronchial epithelial cells, which acquire
other critical genetic changes necessary for lung tumori-
genesis.
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